XENETIC BIOSCIENCES, INC. Payments to Acquire in Process Research and Development
XENETIC BIOSCIENCES, INC. (XBIO) reported Payments to Acquire in Process Research and Development of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2024-03-21
- XENETIC BIOSCIENCES, INC. payments to acquire in process research and development for the quarter ending 2023-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. payments to acquire in process research and development for the quarter ending 2023-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. payments to acquire in process research and development for the quarter ending 2022-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. payments to acquire in process research and development for the quarter ending 2022-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. payments to acquire in process research and development for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- XENETIC BIOSCIENCES, INC. payments to acquire in process research and development for fiscal 2022 was $500.00K.
- XENETIC BIOSCIENCES, INC. payments to acquire in process research and development for fiscal 2021 was $0.00.
| Period end | Payments to Acquire in Process Research and Development 3 month | Payments to Acquire in Process Research and Development 6 month | Payments to Acquire in Process Research and Development 9 month | Payments to Acquire in Process Research and Development 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $500.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $500.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 10-K · filed 2023-03-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2019-09-30 | $3.03M 10-Q · filed 2019-11-14 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |